ClinicalTrials.gg
CompletedNCT06172257Updated May 1, 2026

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

A Phase 3 interventional study of Dexamethasone ophthalmic suspension (OCS-01) and Vehicle in Diabetic Macular Edema, sponsored by Oculis. Completed at 62 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Oculis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies testing dexamethasone in Macular Edema — 3 open to participants now, 3 under way, 1 of them phase 3. Dexamethasone · Macular Edema.

Enrollment
8th of 55
401 · median 50
Started
2024
the only one that year
Phase 3
14 of 56
1 open now
Registered
55th of 56
by date
Lead sponsor
2 of 56
Oculis

Among the 56 studies testing dexamethasone in Macular Edema, this one is the 8th largest by enrollment of the 55 interventional ones that give a count, is the only one that started in 2024, is one of 14 in phase 3, and was the 55th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

3 of the 56 studies testing dexamethasone in Macular Edema are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing dexamethasone in Macular Edema, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).

Read the detailed description

A Phase 3 Pivotal Double-masked, Randomized, Vehicle-controlled, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in participants with Diabetic Macular Edema

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Topical ophthalmic suspension
  • Eye drop
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a signed form before any study-specific procedures are performed.
  2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).
  3. Have a documented diagnosis of Type 1 or Type 2 diabetes mellitus prior to screening (Visit 1).

Exclusion criteria

Exclusion Criteria (selection):

  1. Have macular edema considered to be because of a cause other than DME.
  2. Have a decrease in BCVA because of causes other than DME.
  3. Have a known history of significant macular ischemia which would prevent gain in visual acuity in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    OCS-01

    dexamethasone ophthalmic suspension,1.5% \[15 mg/mL\]

    Drug: Dexamethasone ophthalmic suspension (OCS-01)

  • Placebo comparator
    Vehicle ophthalmic suspension

    Vehicle of OCS-01

    Drug: Vehicle

Interventions

  • Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

    Also known as: Dexamethasone

  • DrugVehicle

    Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in BCVA (Best Corrected Visual Acuity)

    Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the ETDRS chart representing better visual acuity.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants With a 3-line or Greater Gain in BCVA

    BCVA will be assessed using ETDRS letters score: higher numbers on the ETDRS chart representing better visual acuity.

    Time frame: Baseline, Week 52

  2. Mean Change in BCVA

    BCVA will be assessed using ETDRS letters score: higher numbers on the ETDRS chart representing better visual acuity.

    Time frame: Baseline, Week 12 and Week 24

  3. Mean Change in Central Subfield Thickness (CST)

    CST will be measured by spectral domain optical coherence tomography (SD-OCT)

    Time frame: Baseline, Week 52

Other outcomes

  1. Number of Participants with Treatment Emergent Adverse events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant. TEAEs are those AEs that occur after administration of the study product and are therefore temporally associated with the use of the study product.

    Time frame: Up to Week 52

07

Study locations

62 sites
  • Associated Retina Consultants
    Gilbert, Arizona 85297, United States
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Retinal Consultants of Arizona - Phoenix North
    Phoenix, Arizona 85053, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retina Associates of Southern California
    Huntington Beach, California 92647, United States
  • Stanford Byers Eye Institute
    Palo Alto, California 94303, United States
  • Retinal Consultants Medical Group, Inc
    Sacramento, California 95825, United States
  • Retinal Consultants Medical Group
    Sacramento, California 95841, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Macula Retina Vitreous Center
    Torrance, California 90503, United States
  • Retina Specialists of Colorado
    Denver, Colorado 80210, United States
  • Eye Care Center of Northern Colorado
    Longmont, Colorado 80503, United States
  • Sibia Eye Institute
    Boynton Beach, Florida 11195, United States
  • Blue Ocean Clinical Research
    Clearwater, Florida 33761, United States
  • Advanced Research
    Coral Springs, Florida 33067, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • East Coast Institute for Research
    Jacksonville, Florida 32256, United States
  • Retina Consultants of Southwest Florida
    Naples, Florida 33912, United States
  • Marietta Eye Clinic
    Marietta, Georgia 30060, United States
  • Georgia Retina
    Peachtree City, Georgia 30269, United States
  • Illinois Retina Associates
    Oak Park, Illinois 60304, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Mississippi Retina Associates
    Jackson, Mississippi 90033, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • VitreoRetinal Consultants of NY
    Hauppauge, New York 11788, United States
  • Island Retina
    Shirley, New York 11967, United States
  • Vitreoretinal Consultants of NY
    Westbury, New York 11590, United States
  • Erie Retina Research
    Erie, Pennsylvania 16507, United States
  • Vision Research Solutions in Philadelphia
    Philadelphia, Pennsylvania 19141, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina
    Nashville, Tennessee 37203, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Star Retina
    Burleson, Texas 76028, United States
  • Houston Eye Associates, North Loop
    Houston, Texas 77025, United States
  • Austin Retina Associates
    Round Rock, Texas 78681, United States
  • San Antonio Eye Center - Downtown Clinic
    San Antonio, Texas 78215, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Tyler Retina Consultants
    Tyler, Texas 75703, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Fundacion Zambrano
    Buenos Aires, Buenos Aires 1023, Argentina
  • Oftalmos - Instituto Oftalmológico de Alta Complejidad
    Buenos Aires, Buenos Aires C1120 AAN, Argentina
  • Centro De Ojos Loria Srl
    CABA, Buenos Aires 1663, Argentina
  • Centro Privado de Ojos
    CABA, Buenos Aires 1663, Argentina
  • Organizacion Medica De Investigacion
    CABA, Buenos Aires C1015, Argentina
  • Buenos Aires Macula (BAM) Clinical Research
    CABA, Buenos Aires C1061AAE, Argentina
  • Charles Centro Oftalmológico
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1008, Argentina
  • Centro Privado de Ojos Romagosa
    Córdoba, Córdoba Province 5000, Argentina
  • Instituto de Microcirugía Ocular Córdoba (IMOC)
    Córdoba, Córdoba Province X5016KEH, Argentina
  • Oftar Mendoza - Centro Privado de Oftalmología en Mendoza Capital
    Mendoza, Mendoza Province M5500, Argentina
  • Centro de la Vision Dr. Kolton
    Salta, Salta Province A4400, Argentina
  • Grupo Laser Vision
    Rosario, Santa Fe Province S2000 PRB, Argentina
  • Oftalmologìa Global
    Rosario, Santa Fe Province S2000, Argentina
  • Rising Retina Clinic
    Ahmedabad, Gujarat 380015, India
  • Narayana Nethralaya
    Bangalore, Karnataka 560010, India
  • Agrawal Hospital
    Jaipur, Rajasthan 302004, India
  • Lotus Eye Hospital and Institute
    Coimbatore, Tamil Nadu 641014, India
  • St. Theresa's Hospital
    Hyderabad, Telangana 500038, India
  • GSVM Medical College
    Kanpur, Uttar Pradesh 208005, India
  • Emanuelli Research & Development Center
    Arecibo, 00612, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Apr 2026, 24 months.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 15, 2023
StartActual
Mar 15, 2024
Primary completionActual
Apr 2, 2026
CompletionActual
Apr 2, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06172257
Lead sponsor
Oculis
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Mar 15, 2024
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
May 1, 2026

Study contacts

Diana Do, MD
principal investigator · Stanford Byers Eye Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion